A Message from our Founder
“Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only [...]
“Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only [...]
ECAN is proud to have started Esophageal Cancer Awareness Month in 2009. We've been thrilled ever since by all [...]
A First Step for Lucid, perhaps a Giant Leap for Patients at Risk for Esophageal Cancer! In what could [...]
ECAN is offering Esophageal Cancer Patients & Caregivers a special course in Art Journaling. Art journaling is a [...]
A new type of therapy has been approved by the FDA for patients with Gastroesophageal Adenocarcinoma. Learn more. On [...]
ECAN will host a free webinar on Tuesday, March 4, 2025 at 2:15 pm Eastern time to explore the [...]
The Food and Drug Administration (FDA) has approved Zolbetuximab (Vyloy) as a first-line treatment for patients with advanced HER2* [...]
A German study finds a 30% reduction in the risk of death among Esophageal Adenocarcinoma patients who were treated [...]
In 2021, Esophageal Cancer patients and advocates celebrated the Food and Drug Administration’s approval of immunotherapies for patients with [...]
A newly released study of the benefits of the EsoGuard® Esophageal DNA test says it is a powerful screening [...]